<DOC>
	<DOCNO>NCT01963039</DOCNO>
	<brief_summary>Background The standard care patient painful osteoporotic vertebral compression fracture ( VCF ) conservative therapy . Percutaneous vertebroplasty ( PV ) , minimally invasive technique , relatively new treatment option . Recent randomize control trial ( RCT ) provide conflict result : two sham-controlled study show benefit PV unmask control RCT ( VERTOS II ) find effective pain relief acceptable cost patient acute VCFs . A still ongoing mask RCT ( VERTOS IV ) focus acute VCFs define ≤ 6 week . VERTOS III focus conservative treatment find half patient still disable pain 3 month longer . These patient sustain pain 3 month may benefit PV . Objective To compare pain relief PV sham intervention select patient chronic osteoporotic VCF ( three month longer ) use strict inclusion criterion VERTOS II IV . Secondary outcome measure back pain related disability quality life . Methods The VERTOS V study prospective RCT pain relief primary endpoint . Inclusion criterion VCF thoracic level 5 low focal tenderness fracture level , assessed internist physical examination Visual Analogue Scale ( VAS ) score ≥ 5 three month longer , decrease bone density define T score ≤ -1 age 50 year old . 94 patient include , 47 arm . Crossovers allow . Follow-up regular interval one year period VAS score pain primary endpoint . Secondary endpoint back pain related disability quality life measure Quality Life Questionnaire European Foundation Osteoporosis physical function measure Roland Morris Disability questionnaire . Conclusion Vertos V methodologically sound mask randomised sham control trial vertebroplasty patient sustain pain 3 month longer vertebral compression fracture .</brief_summary>
	<brief_title>A Trial Vertebroplasty Painful Chronic Osteoporotic Vertebral Fractures ( Vertos V )</brief_title>
	<detailed_description>available</detailed_description>
	<mesh_term>Fractures , Bone</mesh_term>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Spinal Fractures</mesh_term>
	<mesh_term>Lidocaine</mesh_term>
	<mesh_term>Bupivacaine</mesh_term>
	<mesh_term>Polymethyl Methacrylate</mesh_term>
	<criteria>VCF Xray spine ( minimal 15 % loss height ) level VCF Th5 low back pain ≥ 12 week time Xray ≥ 50 year age bone edema MRI fracture vertebral body focal tenderness VCF level decrease bone density Tscores ≤ 1 severe cardiopulmonary condition untreatable coagulopathy systemic local infection spine ( osteomyelitis , spondylodiscitis ) suspect alternative underlying disease ( malignancy ) radicular and/or cauda compression syndrome contraindication MRI</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>95 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>